Acute Myeloid Leukemia (AML) In Elderly: Cytogenetic Characteristics of Patients Treated At Hematology and Pediatric Oncology Center in Casablanca
- PMID: 30607185
- PMCID: PMC6311475
- DOI: 10.3889/oamjms.2018.484
Acute Myeloid Leukemia (AML) In Elderly: Cytogenetic Characteristics of Patients Treated At Hematology and Pediatric Oncology Center in Casablanca
Abstract
Aim: The goals of this paper are: to report the incidence of AML in elderly, to describe cytogenetic characteristics of this population, to observe rare and novel cytogenetic abnormalities and lastly, to compare our finding with that previously reported in the literature.
Methods: We conducted a retrospective analysis of 283 patients with acute myeloid leukaemia (AML) treated in our unit, we will report the incidence of AML in elderly, describe cytogenetic characteristics of this population, observe rare and novel cytogenetic abnormalities and compare our finding with that previously reported in the literature.
Results: Among the 283 patients, 157 (54.4%) patients performed the karyotype, the cytogenetic analysis failed in 17 cases (11%). Prognostic group distribution was found to be favorable in 8 patients (6%) with 6 cases of t (8; 21) and 2 cases of inv (16), intermediate group in 94 patients (67%), including 58 cases (41,5%) with a normal karyotype, and an unfavorable group in 38 patients (27%) including complex karyotype (15%), -5 or del 5q (3%), -7 or del 7q (3.5%), t (9; 22) (2%). Some rare anomalies were observed.
Conclusion: However, the occurrence of a complex karyotype was more frequent than younger patients. In our unit, elderly benefit from supportive care, our study shows that it is a heterogeneous group and our treatment approach have to change especially for the patient from favourable risk group who can benefit from intensive chemotherapy. We have to improve our diagnosis with including molecular genetics that provides a documented substrate for a thoughtfully considered treatment plan.
Keywords: Acute Myeloblastic leukaemia in older; Adults; Chromosome abnormalities; Cytogenetics.
Similar articles
-
Importance of assessing cytogenetic and molecular risk factors in acute myeloid leukemia therapy.J Med Life. 2012 Oct-Dec;5(Spec Issue):36-43. J Med Life. 2012. PMID: 31803284 Free PMC article.
-
Influence of cytogenetic abnormalities on outcome after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission.Biol Blood Marrow Transplant. 2002;8(8):435-43. doi: 10.1053/bbmt.2002.v8.pm12234169. Biol Blood Marrow Transplant. 2002. PMID: 12234169
-
[Molecular and cytogenetic prognostic factors in acute myeloid leukemia (AML)].Postepy Hig Med Dosw (Online). 2011 Mar 21;65:158-66. doi: 10.5604/17322693.935753. Postepy Hig Med Dosw (Online). 2011. PMID: 21502692 Polish.
-
The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patients.Leukemia. 2001 Jun;15(6):903-9. doi: 10.1038/sj.leu.2402142. Leukemia. 2001. PMID: 11417475 Review.
-
Relapse and cytogenetic evolution in myeloid neoplasms.Panminerva Med. 2017 Dec;59(4):308-319. doi: 10.23736/S0031-0808.17.03380-8. Panminerva Med. 2017. PMID: 29144072 Review.
Cited by
-
Long-Term Outcomes of Patients with Acute Myelogenous Leukemia Treated with Myeloablative Fractionated Total Body Irradiation TBI-Based Conditioning with a Tacrolimus- and Sirolimus-Based Graft-versus-Host Disease Prophylaxis Regimen: 6-Year Follow-Up from a Single Center.Biol Blood Marrow Transplant. 2020 Feb;26(2):292-299. doi: 10.1016/j.bbmt.2019.09.017. Epub 2019 Sep 16. Biol Blood Marrow Transplant. 2020. PMID: 31536825 Free PMC article.
References
-
- Juliusson G, Lazarevic V, Hörstedt AS, Hagberg O, Höglund M. Swedish Acute Leukemia Registry Group Acute myeloid leukemia in the real world: why population-based registries are needed. Blood. 2012;119(17):3890–3899. https://doi.org/10.1182/blood-2011-12-379008 PMid:22383796 PMCid: PMC3358248. - PMC - PubMed
-
- Ossenkoppele G, Löwenberg B. How I treat the older patient with acute myeloid leukemia. Blood. 2015;125(5):767–74. https://doi.org/10.1182/blood-2014-08-551499 PMid:25515963. - PubMed
-
- Hasserjian RP, Campigotto F, Klepeis V, Fu B, Wang SA, Bueso-Ramos C. De novo acute myeloid leukemia with 20–29% blasts is less aggressive than acute myeloid leukemia with >/=30% blasts in older adults: a Bone Marrow Pathology Group study. Am J Hematol. 2014;89(11):E193–9. https://doi.org/10.1002/ajh.23808 PMid:25042343. - PubMed
-
- Medeiros BC, Satram-Hoang S, Hurst D, Hoang KQ, Momin F, Reyes C. Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States. Ann Hematol. 2015;94(7):1127–1138. https://doi.org/10.1007/s00277-015-2351-x PMid:25791241 PMCid: PMC4432101. - PMC - PubMed
-
- Benett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of acute leukemias French-American British (FAB) co-operative group. Br J Haematol. 1976;33:451–8. https://doi.org/10.1111/j.1365-2141.1976.tb03563.x. - PubMed
LinkOut - more resources
Full Text Sources